Chief Executive Officer

Tufail Syed

Tufail has over 19 years of exposure to clinical trials business through engagements such as at Eli Lilly and Company, Medpace and Covance where Tufail held key global senior management and executive roles. Most recently, Tufail was CEO at Q-Pharm, a leading Australian Phase I clinical trials company. He led the company through an accelerated growth phase and M&A process. Tufail has a proven track record of being a strong business leader with deep expertise in leading business transformation and expansion.

Having diverse experience as a physician, basic researcher, medical affairs professional and a global business leader, Tufail combines unique skills to lead Clinexa Life Sciences in Austrlia and Asia Pacific region. Tufail trained as a physician in India and the USA, and earned his MBA from Rutgers Business School, New Jersey. Tufail is passionate about bringing new medicines and therapies to patients sooner and improving lives through clinical research. Tufail founded the world’s largest clinical research society in 2006. He is also a member of the Australian Institute of Company Directors.

Managing Director

Ishrat Ali

Ishrat has overall responsibility of all global operations for Clinexa Life Sciences. Ishrat has a strong background in Finance and Accounting. She has held roles of significant responsibilities in KPMG, ING, AMP Bank and Marsh & McLennan. Ishrat provides strong leadership with acute focus on maintaining a profitable unit that is operating at costs that bring immense value to our clients.

Head - Finance and Administration

Rob Box

Rob has a Master of Commerce and is a member of the Institute of Chartered Accountants with over 30 years of experience in finance. He brings knowledge and experience from a variety of industries including Manufacturing, Retail, and the Motor Industry. His career also includes 14 years as Manager and Owner of a distribution company. Until recently, Rob was with Q-Pharm for over 10 years heading the Finance and Administration function. Rob brings a passion for Finance, Planning and Analysis to the Clinexa Management team.

Head - Clinical Development

Mufti Suhail Sayeed

DNB (Pathology), MS Translational Medicine (Edin.), MBA

Suhail is a board-certified clinical pathologist and translational drug development professional with extensive experience in the design and execution of early phase clinical trials and non-clinical regulatory studies in diverse therapeutic areas like oncology, metabolics, dermatology and infectious diseases.

Suhail completed his pathology residency from the National Board of Examinations (DNB, India) and translational medicine training at the University of Edinburgh. Suhail has been in various leadership roles at Piramal Enterprises NCE Research, Cognizant Life Sciences and Venus Medicine Research Center and is currently working as the Director for Strategy and Operations, Department of Translational Medicine and Therapeutics at HealthCare Global Enterprises Ltd (HCG Oncology). Suhail brings strong experience to help provide solutions for translational medicine and drug development needs.

Clinical Development Advisor

Brad Joblin PhD

Brad has a doctorate from the University of Zurich. Having held senior management and scientific leadership roles in clinical research at the headquarters of global pharmaceutical companies and smaller biotech companies, Brad’s experience is in clinical study implementation, early and late phase clinical study design and clinical development strategy. Bradley founded his own consulting company providing clinical study and development advice to the clinical research community including biotech companies and medical research institutes. Brad provides overall scientific oversight and management at Clinexa.

Medical Director - Oncology

Adeola Ayoola

MBBS FRACP

Dr Adeola Ayoola is a medical oncologist and molecular imaging (Nuclear Medicine) specialist with a keen interest in precision oncology using theranostics and genomic markers to provide specialised (personalised medicine) oncology care to patients. Dr Ayoola currently treats all tumours with a special emphasis on prostate (including radioligand theranostics), gastro-intestinal and breast cancers.

Dr Ayoola has had the privilege to work across different countries with over fourteen years’ experience as a clinician. He started his post graduate training in New Zealand and subsequently specialised in Medical Oncology at the Mater Hospital in Newcastle. He completed a Research Fellowship at the Flinders Medical Center in Adelaide. With a specialised interest in the role of theranostics in cancer care, Dr Ayoola proceeded to further post-specialist training in the applications of Molecular Imaging (Nuclear Medicine) to delivery of precision oncology.

Dr Ayoola collaborates with other genomic experts to deliver cancer genome analysis; this personalised approach explores other potential treatment modalities based on specific mutations present
in those cancer cells.